Overexpression of MiR-361-5p in Triple-negative Breast Cancer (TNBC) Inhibits Migration and Invasion by Targeting RQCD1 and Inhibiting the EGFR/PI3K/Akt Pathway
Overview
Affiliations
Triple-negative breast cancer (TNBC) is the leading cause of cancer-related death in women. Previous studies indicated that miR-361-5p was downregulated in breast cancer, however, the exact effect of miR-361-5p on TNBC requires further investigation. In the present study, we investigated whether miR-361-5p can act as a tumor suppressor by targeting required for cell differentiation 1 homolog (RQCD1) and inhibiting epidermal growth factor receptor (EGFR)/phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway in TNBC. The expression of miR-361-5p and RQCD1 was determined by quantitative reverse transcription PCR (qRT-PCR) and/or western blot in TNBC and the adjacent tissues. miR-361-5p mimics were constructed and transfected to TNBC cell line MDA-MB-231. Cells were divided into three groups: blank control group, miRNA mimic negative control (NC) group, and miR-361-5p mimics group. Expression of miR-361-5p, mRNA and protein expression of PI3K, Akt, EGFR, phosphorylated (p)-EGFR/PI3K/Akt, and protein expression of RQCD1 and matrix metallopeptidase 9 (MMP-9) in MDA-MB-231 were measured by qRT-PCR/western blot after transfection. Cell viability was determined by CCK-8 assay. Cell migration and invasion ability were evaluated by scratch and transwell assay, respectively. miR-361-5p target gene was determined by bioinformatics analysis and luciferase reporter assay. RQCD1 was identified as a target of miR-361-5p by TargetScan and confirmed by luciferase reporter assay. Downregulated miR-361-5p and upregulated RQCD1 were observed in TNBC tissues. Expression of EGFR, PI3K, Akt and MMP-9 was inhibited in cells treated with miR-361-5p mimics. Transfection of miR-361-5p mimics also inhibited the phosphorylation of EGFR, PI3K, and Akt. Suppressed cell viability, migration, and invasion was found in miR-361-5p mimics groups. Our results indicated that overexpression of miR-361-5p might act as a suppressor in TNBC by targeting RQCD1 to inhibit the EGFR/PI3K/Akt signaling pathway.
Durrani I, John P, Bhatti A, Khan J Heliyon. 2024; 10(17):e36650.
PMID: 39281650 PMC: 11401126. DOI: 10.1016/j.heliyon.2024.e36650.
Mehrtabar E, Khalaji A, Pandeh M, Farhoudian A, Shafiee N, Shafiee A Med Oncol. 2024; 41(9):222.
PMID: 39120634 DOI: 10.1007/s12032-024-02469-4.
Ari Yuka S, Yilmaz A BioData Min. 2024; 17(1):11.
PMID: 38627780 PMC: 11022475. DOI: 10.1186/s13040-024-00362-4.
Lee K, Seo E, Lee J, Kim H, Hwangbo C Int J Mol Sci. 2023; 24(11).
PMID: 37298370 PMC: 10253468. DOI: 10.3390/ijms24119418.
Pishbin F, Ziamajidi N, Abbasalipourkabir R, Najafi R, Farhadian M Indian J Clin Biochem. 2023; 38(3):338-350.
PMID: 37234179 PMC: 10205927. DOI: 10.1007/s12291-022-01053-9.